During a corporate presentation at the LD 500 investor conference yesterday, NanoViricides (NYSEMKT:NNVC) President & Executive Chairman Anil Diwan, Ph.D., stated that the company is close to selecting a top clinical candidate for the treatment of COVID-19.
He said that preclinical testing in an animal model showed that the company’s candidates were highly effective against a related coronavirus that uses the same ACE2 receptor as SARS-CoV-2 to infect healthy cells.
https://seekingalpha.com/news/3611701-nanoviricides-closing-in-on-covidminus-19-drug
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.